IS5446A - Blöndur ACE (=AUE) tálma og MMP (=UMP) tálma - Google Patents

Blöndur ACE (=AUE) tálma og MMP (=UMP) tálma

Info

Publication number
IS5446A
IS5446A IS5446A IS5446A IS5446A IS 5446 A IS5446 A IS 5446A IS 5446 A IS5446 A IS 5446A IS 5446 A IS5446 A IS 5446A IS 5446 A IS5446 A IS 5446A
Authority
IS
Iceland
Prior art keywords
aue
ump
mmp
ace
inhibitors
Prior art date
Application number
IS5446A
Other languages
English (en)
Inventor
Thomas Peterson Joseph Jr.
Lethan Pressler Milton
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5446(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS5446A publication Critical patent/IS5446A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS5446A 1997-12-23 2000-04-14 Blöndur ACE (=AUE) tálma og MMP (=UMP) tálma IS5446A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23
PCT/US1998/023993 WO1999032150A1 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Publications (1)

Publication Number Publication Date
IS5446A true IS5446A (is) 2000-04-14

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5446A IS5446A (is) 1997-12-23 2000-04-14 Blöndur ACE (=AUE) tálma og MMP (=UMP) tálma

Country Status (24)

Country Link
US (1) US6133304A (is)
EP (1) EP1047450B1 (is)
JP (1) JP2001526245A (is)
KR (1) KR20010033473A (is)
AR (1) AR015504A1 (is)
AT (1) ATE225187T1 (is)
AU (1) AU751701B2 (is)
BR (1) BR9814422A (is)
CA (1) CA2305436A1 (is)
CO (1) CO4970775A1 (is)
DE (1) DE69808518T2 (is)
DK (1) DK1047450T3 (is)
ES (1) ES2184340T3 (is)
HU (1) HUP0100427A3 (is)
IL (1) IL135428A0 (is)
IS (1) IS5446A (is)
NO (1) NO20003256L (is)
NZ (1) NZ503962A (is)
PE (1) PE20000065A1 (is)
PL (1) PL341335A1 (is)
PT (1) PT1047450E (is)
UY (1) UY25321A1 (is)
WO (1) WO1999032150A1 (is)
ZA (1) ZA9811794B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1044935A1 (zh) * 1999-03-03 2002-11-08 The Procter & Gamble Company 双异取代的金属蛋白酶抑制剂
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
EP1419767A4 (en) * 2001-08-20 2005-03-16 Ono Pharmaceutical Co MEDICINE FOR TREATMENT OF HEART FAILURE
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
US7364719B2 (en) * 2002-10-04 2008-04-29 The United States Of America As Represented By The Department Of Health And Human Services Vasoregulating compounds and methods of their use
AU2003295422B2 (en) * 2002-11-07 2009-01-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
WO2005014825A2 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
ES2375706T3 (es) * 2003-11-14 2012-03-05 Baxter International Inc. Composiciones de alfa 1-antitripsina y métodos de tratamiento que usan tales composiciones.
AU2005221151A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US20080269282A1 (en) * 2004-08-02 2008-10-30 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
WO2009155611A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011041545A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
JP2014525443A (ja) 2011-08-30 2014-09-29 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物、およびこれらの使用方法
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2916497C (en) * 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
KR20170026633A (ko) 2014-07-17 2017-03-08 씨에이치디아이 파운데이션, 인코포레이티드 Hiv-관련 장애의 치료 방법 및 치료용 조성물
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227346B1 (en) * 1990-05-11 2011-04-28 Pfizer Process for producing synergetic pharmaceutical composition
EP0808172B1 (en) * 1995-02-10 2003-06-25 G.D. SEARLE & COMPANY Combination of angiotensin converting enzyme inhibitor and aldosterone antagonist for the treatment of ventricular hypertrophy
EE03965B1 (et) * 1996-05-17 2003-02-17 Warner-Lambert Company Maatriksi metalloproteinaasi bifenüülsulfoonamiidinhibiitorid
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
NO20003256D0 (no) 2000-06-22
WO1999032150A1 (en) 1999-07-01
US6133304A (en) 2000-10-17
PT1047450E (pt) 2003-02-28
HUP0100427A3 (en) 2002-11-28
BR9814422A (pt) 2000-10-10
ATE225187T1 (de) 2002-10-15
NO20003256L (no) 2000-06-22
PE20000065A1 (es) 2000-02-11
NZ503962A (en) 2002-03-28
UY25321A1 (es) 2004-07-30
HUP0100427A2 (hu) 2001-06-28
DK1047450T3 (da) 2003-01-27
EP1047450B1 (en) 2002-10-02
JP2001526245A (ja) 2001-12-18
CO4970775A1 (es) 2000-11-07
AU1522099A (en) 1999-07-12
DE69808518T2 (de) 2003-06-26
IL135428A0 (en) 2001-05-20
ZA9811794B (en) 1999-06-29
CA2305436A1 (en) 1999-07-01
AR015504A1 (es) 2001-05-02
EP1047450A1 (en) 2000-11-02
DE69808518D1 (de) 2002-11-07
AU751701B2 (en) 2002-08-22
PL341335A1 (en) 2001-04-09
KR20010033473A (ko) 2001-04-25
ES2184340T3 (es) 2003-04-01

Similar Documents

Publication Publication Date Title
IS5446A (is) Blöndur ACE (=AUE) tálma og MMP (=UMP) tálma
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
NO995433D0 (no) Protease-inhibitorer
FI20085256L (fi) Retrovirusperäisten proteaasi-inhibiittoreiden yhdistelmä
NO990548L (no) Inhibitorer for cystein-protease
NO991922L (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
DK0944590T3 (da) Aminoguanidiner og alkoxyguanidiner som proteaseinhibitorer
ID27394A (id) Kombinasi farmasi yang mengandung inhibitor cox-2 dan inhibitor inos
NO992492D0 (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
ID19198A (id) Inhibitor metaloprotease heterosiklik
ID18416A (id) Inhibitor metaloprotease diheterosiklik
BR9607412A (pt) Inibidor de trombina e composto
NO974403D0 (no) Reversible proteasehemmere
IT1298163B1 (it) Inibitori di solfammido-metalloproteasi
ATE239755T1 (de) Thrombin inhibitoren
NO995435D0 (no) Protease-inhibitorer
FI942625L (fi) Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina
NO995434L (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO992315D0 (no) Benzotiazo og beslektet heterosykliske gruppe-inneholdende cystein og serinprotease inhibitorer
ID21725A (id) Kompresor jenis piringan hentak
EP1090011A4 (en) INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
DE69941152D1 (de) Hydroxamat-enthaltende inhibitoren der cystein- und serinproteasen
DK0929577T3 (da) Stabiliserede proteinholdige protease-inhibitorer og varianter deraf
DK0623614T3 (da) 4-aryl-4-hydroxy-tetrahydropyraner og 3-aryl-3-hydroxy-tetrahydrofuraner som inhibitorer for 5-lipoxygenase